Tempest Therapeutics, Inc. Fair Value of Assets Acquired
Tempest Therapeutics, Inc. (TPST) reported Fair Value of Assets Acquired of $63.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-04-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueOfAssetsAcquired · last filed 2019-04-01
- Tempest Therapeutics, Inc. fair value of assets acquired for fiscal 2017 was $63.00M.
| Period end | Fair Value of Assets Acquired 12 month |
|---|---|
| 2017-12-31 | $63.00M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |